News Nutriband Inc.’s patent, ‘Abuse and Misuse deterrent transdermal system’ published by the United States Patent and Trademark Office following recent issuance notice Read More » February 16, 2022 News Nutriband issued full US patent for its AVERSA™ abuse deterrent transdermal platform by United States Patent and Trademark Office. Read More » January 28, 2022 News Nutriband Inc. Expands Product Development Pipeline for Its AVERSA(TM) Platform Abuse Deterrent Technology Read More » January 18, 2022 News Nutriband Inc. and Kindeva Drug Delivery sign feasibility agreement to develop AVERSA™ Fentanyl, an abuse deterrent fentanyl patch Read More » January 10, 2022 News Nutriband Lead Product Aversa(TM) Fentanyl May Reach Peak Annual Sales of $80-200 Million Based on Market Assessment by Leading Healthcare Consulting Firm Read More » January 5, 2022 News Nutriband Inc. Issued Full Patent from the Korean Intellectual Property Office for Its “Abuse and Misuse Deterrent Transdermal System” Application Read More » December 31, 2021 News Nutriband Inc. Announces $1 Million Share Repurchase Authorization Read More » December 29, 2021 News Nutriband Inc. initiates plans to offer Topical lotion contract manufacturing services Read More » December 21, 2021 News Nutriband Inc. Receives cGMP Certification for Manufacturing Subsidiary Read More » December 13, 2021 « Previous Page1 Page2 Page3 Page4 Page5 Next »
News Nutriband Inc.’s patent, ‘Abuse and Misuse deterrent transdermal system’ published by the United States Patent and Trademark Office following recent issuance notice Read More » February 16, 2022
News Nutriband issued full US patent for its AVERSA™ abuse deterrent transdermal platform by United States Patent and Trademark Office. Read More » January 28, 2022
News Nutriband Inc. Expands Product Development Pipeline for Its AVERSA(TM) Platform Abuse Deterrent Technology Read More » January 18, 2022
News Nutriband Inc. and Kindeva Drug Delivery sign feasibility agreement to develop AVERSA™ Fentanyl, an abuse deterrent fentanyl patch Read More » January 10, 2022
News Nutriband Lead Product Aversa(TM) Fentanyl May Reach Peak Annual Sales of $80-200 Million Based on Market Assessment by Leading Healthcare Consulting Firm Read More » January 5, 2022
News Nutriband Inc. Issued Full Patent from the Korean Intellectual Property Office for Its “Abuse and Misuse Deterrent Transdermal System” Application Read More » December 31, 2021
News Nutriband Inc. Announces $1 Million Share Repurchase Authorization Read More » December 29, 2021
News Nutriband Inc. initiates plans to offer Topical lotion contract manufacturing services Read More » December 21, 2021
News Nutriband Inc. Receives cGMP Certification for Manufacturing Subsidiary Read More » December 13, 2021
